Artrya Ltd FY2026 Annual Report and Appendix 4E
Key points
- FY2026 marked Artrya's transition to commercial-stage business.
- Successful signing of U.S. foundation customers.
- FDA clearance for Salix® Coronary Plaque module.
- Completed $80 million capital raise.
- Expansion of leadership team.
Full summary
Artrya Ltd's 2026 financial year marked a significant transition to a commercial-stage business. The company successfully signed U.S. foundation customers, including Tanner Health, Northeast Georgia Health System, and Cone Health. It secured FDA clearance for the Salix® Coronary Plaque module, enabling subscription-based software revenues. The company completed an $80 million capital raise and finalized the SAPPHIRE Study, a clinical and commercial initiative designed to generate world-class evidence and accelerate adoption across leading health systems. The company also strengthened its commercial capabilities by establishing a U.S.-based Customer Success organization and enhancing its leadership team.
Guidance
FY2026 loss for the year attributable to owners of Artrya Limited up 53.5% to $25,183,000
Outlook
Artrya Ltd expects to secure Salix® Coronary Flow regulatory clearance and continue advancing its work with SAPPHIRE partners.
Summary generated by a large language model. Please interpret with care.